Spacer

 
 

Pipeline to Partnerships (P2P)

Category/Phase: Allergy/Immunology / Phase 2
P2P Home
represents column sort
                                    

Title Company Name Platform / Modality Target Investor/Partner Relations
Oral Clinical Drug for Asthma & COPD Inverseon, Inc. Small Molecules Inflammatory Pathway VC, Licensing, Manufacturing, Strategic Partner
Technology and Device for Asthma Treatment General Innovations &Goods, Inc. Other(Device for asthma and infections control) Reduces airborne allergens and infections agents -The airway inflammation and reactivity associated with asthma will be reduced by lowering the level of exposure to extrinsic factors associated with asthma and by exposing the patient to deactivated airborne allergens. VC, Licensing

  


 
Spacer
Note that this site uses cookies, Click here for more information.